TRDA · Program file
VX-670
Entrada Therapeutics, Inc. (TRDA)
When did Entrada Therapeutics, Inc. say VX-670 results would come?
On , Entrada Therapeutics, Inc. wrote in its SEC Form 10-Q: “Vertex is on track to complete dosing and report results in the second half of 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “second half of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- VX-670
- Other names in filings
- GALILEO
- Indication in the filing
- myotonic dystrophy type 1
- Trials named in the same filing
- None listed
- Latest timing wording
- “Vertex is on track to complete dosing and report results in the second half of 2026.”
- Source
- 10-Q · filed · SEC accepted · accession 0001689375-26-000054 · SEC original
- Last checked
Program TRDA-vx-670.